EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Inhibition of METTL3 Attenuates Renal Fibrosis by Upregulating ABCG2 m6A Modifications via IGF2BP2 ‐Dependent Mechanisms in Hyperuricemic Nephropathy

Tong Zu, Hang Yang, Jie Wang, Shuangjian Li, Yue Yu, Kuo Zhang, Xiuxiu Song, Jie Ying, Yaru Yang, Xian Wang, Juan Jin iD

Journal of Cellular and Molecular Medicine · 2025

DOI: 10.1111/jcmm.70468 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Cellular and Molecular Medicine, 2025. Verfasst von Tong Zu und 10 weiteren Autor:innen. Beteiligte Einrichtung: School of Basic Medicine, School of Pharmacy, Anhui Medical University, Hefei, China. Hauptthemen laut MEDLINE: ATP Binding Cassette Transporter, Subfamily G, Member 2, Hyperuricemia, Methyltransferases, RNA-Binding Proteins. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Hyperuricemia has been linked to kidney problems including hyperuricemic nephropathy (HN), which is characterised by inflammation and fibrosis in the kidneys. HN is frequently observed in patients with chronic gout. However, the causes of HN are not fully understood and effective treatments are limited. The status of RNA m6A, expression, and location of METTL3 in the kidney was evaluated in mice with HN. The mechanism of the METTL3‐associated ABCG2 downregulation was further studied in mTEC cells and a potassium oxazinate + adenine‐induced mice model and adeno‐associated virus 9 (AAV9)‐mediated METTL3 silencing mice. Expressions of ABCG2, α‐SMA, collagen‐1, TGF‐β1, IL‐1β, IL‐6, and TNF‐α were analysed using real‐time PCR and western blotting. Hyperuricemia led to elevated m6A levels and METTL3 expression in mouse kidneys. METTL3 was mainly located in mTEC cells. METTL3‐specific inhibitor STM2457 alleviated uric acid‐induced inflammatory and fibrotic responses in mTEC cells. Mechanistically, ABCG2 was identified as a target of METTL3 by RNA sequencing. The stability of ABCG2 was decreased through the binding of IGF2BP2 (insulin‐like growth factor 2 binding protein 2) to its m6A‐modified stop codon regions. Silencing or inhibition of METTL3 significantly reduced uric acid‐induced cell injury and increased ABCG2 expression, leading to uric acid excretion. In vivo data showed that AAV9‐mediated METTL3 silencing significantly alleviated renal dysfunction and fibrosis in HN mice. Our study provides the first evidence that METTL3 regulates uric acid excretion by controlling the m6A levels of ABCG2 through the binding of IGF2BP2, and inhibiting METTL3 can effectively alleviate kidney damage caused by hyperuricemia, showing potential as a therapy for HN.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ATP Binding Cassette Transporter, Subfamily G, Member 2HyperuricemiaMethyltransferasesRNA-Binding ProteinsKidney DiseasesNeoplasm ProteinsAdenosineAnimalsMiceFibrosisMaleHumansDisease Models, AnimalUp-RegulationMice, Inbred C57BLKidney

Stichwörter der Autor:innen

ABCG2IGF2BP2METTL3hyperuricemiamRNA m6A

Substanzen

ATP Binding Cassette Transporter, Subfamily G, Member 2MethyltransferasesRNA-Binding ProteinsMettl3 protein, mouseAbcg2 protein, mouseNeoplasm ProteinsAdenosine

Autor:innen und Institutionen

  • School of Basic Medicine, School of Pharmacy, Anhui Medical University, Hefei, China.
  • Inflammation and Immune Mediated Diseases Laboratory of Anhui Province, Anhui Institute of Innovative Drugs, School of Pharmacy, Anhui Medical University, Hefei, Anhui, China.
  • Department of Clinical Pharmacology, The Second Affiliated Hospital of Anhui Medical University, Hefei, Anhui, China.
  • Department of Nephrology, Fuyang People's Hospital of Anhui Medical University, Fuyang, Anhui, China.

ORCID-Profile: Juan Jin

Förderung

  • National Natural Science Foundation of China

Zitieren

APA

Zu, T., Yang, H., Wang, J., Li, S., Yu, Y., Zhang, K., Song, X., Ying, J., Yang, Y., Wang, X., & Jin, J. (2025). Inhibition of METTL3 Attenuates Renal Fibrosis by Upregulating ABCG2 m6A Modifications via IGF2BP2 ‐Dependent Mechanisms in Hyperuricemic Nephropathy. Journal of Cellular and Molecular Medicine. https://doi.org/10.1111/jcmm.70468

Vancouver

Zu T, Yang H, Wang J, Li S, Yu Y, Zhang K, et al. Inhibition of METTL3 Attenuates Renal Fibrosis by Upregulating ABCG2 m6A Modifications via IGF2BP2 ‐Dependent Mechanisms in Hyperuricemic Nephropathy. Journal of Cellular and Molecular Medicine. 2025. doi:10.1111/jcmm.70468

BibTeX
@article{Zu2025,
  author = {Zu, Tong and Yang, Hang and Wang, Jie and Li, Shuangjian and Yu, Yue and Zhang, Kuo and Song, Xiuxiu and Ying, Jie and Yang, Yaru and Wang, Xian and Jin, Juan},
  title = {Inhibition of METTL3 Attenuates Renal Fibrosis by Upregulating ABCG2 m6A Modifications via IGF2BP2 ‐Dependent Mechanisms in Hyperuricemic Nephropathy},
  journal = {Journal of Cellular and Molecular Medicine},
  year = {2025},
  doi = {10.1111/jcmm.70468}
}
Kostenlos starten →